Citrosil Antibacterial Disinfectant Gauzes 0.175% Benzalkonium Chloride 8 Gauzes

100 ml of cutaneous solution contain: ACTIVE INGREDIENT: benzalkonium chloride g 0.175. For the full list of excipients, see section 6.1.

Lemon essence, thyme essence, ethyl alcohol, polysorbate 20, edetate tetrasodium, quinoline yellow (E 104), patent blue (E 131), hydrochloric acid, purified water.

Disinfection and cleaning of even injured skin (wounds, grazes, abrasions, burns).

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Do not administer to children under 1 year of age.

Use the handkerchief on the area to be disinfected two - three times a day. DO NOT EXCEED THE RECOMMENDED DOSE

Store in the original package to protect the medicine from light and heat.

The product is for external use only. Avoid contact with the eyes, brain, meninges and middle ear. Do not use for prolonged treatments. After a short period of treatment without noticeable results, consult your doctor. Do not use for the disinfection of mucous membranes. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena; in this case, stop the treatment and consult your doctor. The accidental ingestion or inhalation of some disinfectants can have serious, sometimes fatal, consequences. Avoid exposure to ultraviolet rays (sun or artificial sources) after applying the product.

Avoid the simultaneous use of other antiseptics and detergents. Pediatric population Interaction studies have only been performed in adults.

The following adverse reactions have been identified after authorization for the use of benzalkonium chloride. Since these reactions arise from spontaneous reports, it is not always possible to define their frequency. It is possible, in some cases, the occurrence of intolerance (burning or irritation), however without consequences, which does not require modification of the treatment. Pediatric population The same frequency, type and severity of undesirable effects are expected in the pediatric population as in the adult population. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it/it/responsabili.

Under normal conditions of use no overdose damage has been reported. Accidental ingestion can cause nausea and vomiting. Symptoms of intoxication resulting from the ingestion of significant quantities of quaternary ammonium compounds include dyspnoea, cyanosis, asphyxia, resulting from paralysis of the respiratory muscles, CNS depression, hypotension and coma. In humans, the lethal dose is approximately 1-3g. Treatment of poisoning is symptomatic: administer soothing if necessary. Avoid emesis and gastric lavage.

Pregnancy The product should be used only in cases of real need. During the period of breastfeeding, avoid applying the product to the breast to avoid ingestion of the product by the infant.